Pluristem slumps as FDA suspends stem cell study

June 5, 2013

Pluristem Therapeutics Inc. said Tuesday the Food and Drug Administration suspended a clinical trial of one of its stem cell therapies, sending the company’s shares lower. (Businessweek)